Nike vs. Procter & Gamble: Which Consumer Stock Is a Better Buy in 2026?

The comparison favors Procter & Gamble over Nike: P&G reported FY2026 revenue of about $87.0B, up 3.3%, net income near $16B and a 18.4% net margin, while Nike revenue was about $46.4B, up roughly 0.2%, with $3.1B net income and a 6.7% margin. Nike expects sales to decline in FY2027; its shares were down 44.5% over the prior 12 months, while P&G shares were up 4.5%. P&G also reported fiscal Q3 sales of $21.2B, up 7% year over year, and has raised its dividend for 70 consecutive years.

Analysis

The key distinction is earnings durability, not the apparent sales-multiple discount. NKE’s low price-to-sales ratio is consistent with materially weaker profitability and near-term revenue risk; it is not, by itself, evidence of mispricing. At roughly comparable forward earnings multiples in the article, the market may already be assigning value to a recovery while requiring evidence that product demand, wholesale relationships, and margins can stabilize. A further FY27 outlook cut would put that recovery premium at risk. The three largest U.S. customers’ share of U.S. sales also makes NKE more exposed to retailer inventory and bargaining decisions than a brand-only narrative suggests; the stated concentration is not a share of total company sales.

PG’s steadier demand and cash generation offer a defensive counterweight, but Walmart’s roughly 16% share of PG sales creates a meaningful customer-negotiation and shelf-access dependency. Private-label substitution can constrain price increases even when category volumes hold up. The reported quarterly and annual growth rates should not be compared without checking period, currency, and organic-growth definitions. Likewise, absolute debt is not a useful leverage comparison without maturities, interest costs, and cash-flow coverage.

Near term, the relative trade is vulnerable to a broad risk-on rotation or an NKE earnings surprise. Over 1–3 months, NKE guidance and sell-through evidence matter more than the low sales multiple; over 6–18 months, successful product and channel execution could close the performance gap. Falsify the defensive-relative thesis if NKE restores growth and improves margins while PG’s organic volume or guidance weakens.

Key Decisions for Investors

• Consider a modest, volatility-adjusted long PG / short NKE relative-value position rather than treating NKE’s lower sales multiple as a standalone buy signal. Reassess after the next earnings and guidance updates; the pair can lose if NKE delivers a credible recovery or defensive staples de-rate.
• For NKE, wait for evidence of improving sell-through, earnings execution, and a stable or upgraded FY27 outlook before adding. A further guidance reduction or continued margin deterioration would invalidate a turnaround entry; verify wholesale inventory and direct-channel trends rather than relying on brand claims.
• For PG, retain a defensive bias but monitor organic volume, pricing, and Walmart-related commentary. Weakening volume or evidence that retailer/private-label pressure is limiting price realization would challenge the stability premium.
• Before acting on the reported valuation or growth comparisons, verify the fiscal periods, forward-estimate definitions, organic versus reported sales, and current prices; the article’s figures alone do not establish relative cheapness.